TNSN08271A1 - Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers - Google Patents
Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymersInfo
- Publication number
- TNSN08271A1 TNSN08271A1 TNP2008000271A TNSN08271A TNSN08271A1 TN SN08271 A1 TNSN08271 A1 TN SN08271A1 TN P2008000271 A TNP2008000271 A TN P2008000271A TN SN08271 A TNSN08271 A TN SN08271A TN SN08271 A1 TNSN08271 A1 TN SN08271A1
- Authority
- TN
- Tunisia
- Prior art keywords
- sustained release
- octreotide
- polylactide
- release formulation
- glycolide polymers
- Prior art date
Links
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title abstract 2
- 108010016076 Octreotide Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960002700 octreotide Drugs 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polyesters Or Polycarbonates (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119086 | 2006-08-17 | ||
| PCT/EP2006/012313 WO2007071395A1 (en) | 2005-12-22 | 2006-12-20 | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN08271A1 true TNSN08271A1 (en) | 2009-10-30 |
Family
ID=37216009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2008000271A TNSN08271A1 (en) | 2006-08-17 | 2008-06-20 | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TNSN08271A1 (en) |
-
2008
- 2008-06-20 TN TNP2008000271A patent/TNSN08271A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03936A (en) | ||
| TN2011000261A1 (en) | Octreotide depot formulation with constantly high exposure levels | |
| IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
| WO2008052033A3 (en) | Ibuprofen composition | |
| WO2009100441A3 (en) | Depot formulations | |
| MX2010004576A (en) | Novel pyrimidine derivatives. | |
| WO2008006528A3 (en) | Pharmaceutical compositions comprising levetiracetam | |
| MX2010005889A (en) | Novel thiophene derivatives. | |
| IL214617A0 (en) | Use of controlled release formulations of octreotide | |
| ZA200705530B (en) | Sustained release pharmaceutical formulations | |
| WO2010017215A3 (en) | Biodegradable microspheres and methods of use thereof | |
| WO2010111640A3 (en) | Anti-influenza formulations and methods | |
| MX2010008365A (en) | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers. | |
| TW200942524A (en) | Novel aminomethyl benzene derivatives | |
| WO2014096985A3 (en) | A stable aqueous composition comprising human insulin or an analogue or derivative thereof | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| IL185542A0 (en) | Compositions having sustained -release insect repellency | |
| IL191758A0 (en) | Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof | |
| MX2007003196A (en) | Agent and food for preventing/improving functional digestive disorder. | |
| WO2008145475A8 (en) | Oral care composition | |
| TR200806300A2 (en) | Solubility enhancing pharmaceutical formulation | |
| WO2009133083A3 (en) | Herbicide mixture | |
| WO2007137216A3 (en) | Gastroretentive sustained release formulations | |
| TNSN08271A1 (en) | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers | |
| TR201009399A2 (en) | Rapidly soluble effervescent rosuvastatin formulations. |